Illumina Stock Up 16.7 Percent After Robert W. Baird Upgrade

genomeweb
360dx

Illumina Stock Up 16.7 Percent After Robert W. Baird Upgrade

Mar 30, 2005

NEW YORK, March 30 (GenomeWeb News) - Shares in Illumina were up 16.76 percent, or $1.17, at $8.15 in mid-afternoon trading after Robert W. Baird upgraded the company's stock to "outperform" from "neutral."

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Glaucoma Risk Factor Linked to More Than 100 Genetic Loci in Europeans
Pfizer to Offer $1.5M in Grant Funding to Support BRCA Testing
Human Malaria Parasite's Evolution Refined by Genomes of Great Ape Pathogens
Foundation Medicine's Stock Rises on Approval of Test as New ADLT
IncellDx Gets CE Mark for HPV Assay
Top Five Articles on GenomeWeb Last Week: Illumina, 23andMe, Siemens Healthineers, and More

The Scan

New Nature EIC Talks Transparency

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic Genealogy for Another Arrest

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

This Week in PLOS

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Working With Others

Wired reports that 23andMe is trying to bolster its outside collaborations.

Main menu